⌕
Kura Oncology · KURA · Nasdaq
Tenet 30 · Weak
Compare
$7.49+5.64%At closeTenet 30 · Weak
$7.49+0.40 (+5.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kura Oncology (KURA) Stock

Kura Oncology (KURA) closed at $7.49 on Nov 17, 2026; its Tenet Score is 30 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

26 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$7.49
Nov 17, 2026
Market cap
$651.4M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.75 – 13.90
low → high · as of close, Nov 16, 2026
Tenet Score
30/100
Weak · 340 Healthcare peers

Industry: Drugs

Kura Oncology Inc scores 30/100. Weak. Value is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 30 is built from 3 of 4 pillars, from 45% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=340
30/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
5
Quality
26
Health
58
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityFHealthCGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
36.3×
Sep 30, 2026 balance sheet
P/S
8.2×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is under 5% of total assets.
Operating margin
−449.9%
fiscal 2025, before interest and tax
Net margin
−369.3%
TTM through Sep 30, 2026
Current ratio
3.60
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are zi…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 65 US ETFs · top wrappers by weightSee all ETFs holding KURA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Kura Oncology in?

Kura Oncology is in the Healthcare sector and the Drugs industry.

What is Kura Oncology's Tenet Score?

Kura Oncology's Tenet Score is 30 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.